
Ajanta Pharma Ltd. is Rated Hold by MarketsMOJO
2026-05-07 10:10:27Ajanta Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 23 Mar 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news articleAre Ajanta Pharma Ltd. latest results good or bad?
2026-05-06 19:15:51Ajanta Pharma Ltd. reported its Q4 FY26 results, showcasing a strong revenue performance alongside some concerns regarding profitability. The company achieved net sales of ₹1,421.64 crores, reflecting a year-on-year growth of 21.47%, which is significantly higher than the previous year's growth of 11.04%. This marks the highest quarterly revenue in the company's history, indicating robust demand and effective market strategies. However, the financial results also revealed challenges in maintaining profitability. The net profit for the quarter stood at ₹266.70 crores, representing an 18.40% increase year-on-year, yet it experienced a sequential decline of 2.58% from the previous quarter. This decline raises questions about the sustainability of profit levels despite strong sales growth. A notable concern is the contraction in operating margins, which fell to 23.45% from 27.80% in the previous quarter, indi...
Read full news article
Ajanta Pharma Ltd. Surges 7.24% to Day's High of Rs 3111.5 — Outperforms Sector by 4.72 Percentage Points
2026-05-06 12:45:49The Sensex edged lower by 0.12% on 6 May 2026, while Ajanta Pharma Ltd. surged 7.24%, touching an intraday high of Rs 3111.5. This 4.72-percentage-point outperformance over the Pharmaceuticals & Biotechnology sector’s 2.14% gain highlights a distinctly stock-specific rally rather than a broad market lift.
Read full news article
Ajanta Pharma Reports Flat Quarterly Performance Amidst Strong Historical Returns
2026-05-06 08:00:05Ajanta Pharma Ltd., a key player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended March 2026, marking a notable shift from its previously positive growth trajectory. Despite achieving its highest-ever quarterly net sales, the company’s overall financial trend score has declined, prompting a reassessment of its market stance and investor outlook.
Read full news article
Ajanta Pharma Q4 FY26: Strong Topline Growth Masks Margin Pressure Concerns
2026-05-05 21:45:33Ajanta Pharma Ltd., a specialty pharmaceutical formulations company with operations across India, Asia, and Africa, reported a mixed performance for the quarter ended March 2026, with robust revenue growth offset by declining profitability on a sequential basis. The company posted a consolidated net profit of ₹266.70 crores for Q4 FY26, representing a marginal decline of 2.58% quarter-on-quarter but a healthy gain of 18.40% year-on-year. With a market capitalisation of ₹36,144 crores, the stock traded at ₹2,900.90 as of May 05, 2026, down 0.11% from the previous close.
Read full news article
Ajanta Pharma Ltd. Exhibits Mildly Bullish Momentum Amid Mixed Technical Signals
2026-04-30 08:00:26Ajanta Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently exhibited a subtle shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. Despite a mixed bag of technical indicator signals, the stock’s price action and relative strength suggest cautious optimism for investors navigating the current market environment.
Read full news article
Ajanta Pharma Ltd. Technical Momentum Shifts Amid Mixed Market Signals
2026-04-29 08:00:26Ajanta Pharma Ltd., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. Recent technical indicators reveal a complex picture, with bearish signals on weekly and monthly MACD and KST, while moving averages and Bollinger Bands offer mixed cues. This article analyses these technical developments in detail, placing them in the context of the stock’s recent price action and relative performance against the Sensex.
Read full news article
Ajanta Pharma Ltd. is Rated Hold by MarketsMOJO
2026-04-26 10:10:24Ajanta Pharma Ltd. is rated 'Hold' by MarketsMOJO, with this rating last updated on 23 March 2026. While the rating was revised on that date, the analysis and financial metrics presented here reflect the company’s current position as of 26 April 2026, providing investors with the most up-to-date view of the stock’s fundamentals, returns, and technical outlook.
Read full news articleAnnouncement under Regulation 30 (LODR)-Newspaper Publication
06-May-2026 | Source : BSEPlease find enclosed the Newspaper Publication of Financial Results for the quarter and year ended 31st March 2026
Board Meeting Outcome for Outcome Of Board Meeting
05-May-2026 | Source : BSEPFA BM Outcome
Intimation Of Grant And Cancellation Of Options
05-May-2026 | Source : BSEPFA Intimation w.r.t grant and cancellation of ESOPs
Corporate Actions
No Upcoming Board Meetings
Ajanta Pharma Ltd. has declared 1400% dividend, ex-date: 10 Nov 25
Ajanta Pharma Ltd. has announced 2:5 stock split, ex-date: 20 Mar 15
Ajanta Pharma Ltd. has announced 1:2 bonus issue, ex-date: 22 Jun 22
No Rights history available






